EXPLOITING NOVEL THERAPEUTIC TARGETS IN MULTIPLE MYELOMA (K23M)

描述(由申请人提供)：骨髓瘤和其他B细胞恶性肿瘤的新治疗策略的开发需要临床研究人员和基础科学家之间的合作努力。显然需要在患者护理、临床试验设计和基础科学原理方面具有技能的个人，他们能够在这些和其他形式的癌症的新治疗的构思、开发和评估中弥合替补和床边之间的差距。作为该项目的首席研究员，Niesvizky博士致力于进一步开展他的研究活动，并为他的职业发展接受进一步的指导培训，以填补这一长期角色。为了获得必要的技能，战略是走一条教育和研究道路，包括： 1)在Bergsagel博士和Chen-Kiang博士的指导下，开发和执行一项翻译研究，以评估选定的有希望的药物在多发性骨髓瘤治疗中的效果。 2)与Scott Wadler博士以及通过包括康奈尔大学普通临床研究中心和Weill医学研究生院在内的几个机构资源，在临床试验设计方面进行授课和指导培训。 3)使用新的药物和组合开发和执行研究人员发起的治疗骨髓瘤的临床试验。尼斯维茨基博士的研究重点是药物开发。在这项为期五年的综合计划之后，他将获得独立的临床研究技能，与基础科学合作者合作，领导一个药物开发和其他骨髓瘤新疗法的转化研究计划。预计这项工作将对这种疾病和其他B细胞恶性肿瘤患者的护理做出重大贡献。

DESCRIPTION (provided by applicant): Development of novel therapeutic strategies in myeloma and other B-cell malignancies requires collaborative efforts between clinical researchers and basic scientists. There is a clear need for individuals with skills in patients care, clinical trial design, and basic science principles who can bridge the gap between the bench and the bedside in the conception, development and evaluation of new treatment in these and other forms of cancer. As the principal investigator in this project, Dr Niesvizky is dedicated to further his research activities and undergo further mentored training for his career development to fill this long-term role. In order to attain the necessary skills, the strategy is to follow an educational and research path including: 1) Development and execution of a translational study to evaluate the effect of selected promising agents in the treatment of multiple myeloma under the tutoring of Drs. Bergsagel and Chen-Kiang. 2) Didactic and mentored training in clinical trial design with Dr Scott Wadler, as well as through several institutional resources including the General Clinical Research Center and the Weill Graduate School of Medical Sciences of Cornell University. 3)Development and execution of investigator-initiated clinical trials for myeloma using novel agents and combinations. Dr Niesvizky's research is focused in drug development. Following this five-year comprehensive program, he will attain the independent clinical research skills to work with basic science collaborators to lead a translational research program in drug development and other novel treatments for myeloma. It is expected that this work will significantly contribute to the care of patients with this disease and other B-cell malignancies.